Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.54 |
| ▸ | CA2 | P00918 | 9/20 | 0.54 |
| ▸ | CA9 | Q16790 | 7/20 | 0.54 |
| ▸ | CA12 | O43570 | 7/20 | 0.54 |
| ▸ | CA5A | P35218 | 2/20 | 0.54 |
| ▸ | CA4 | P22748 | 2/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.54 |
| ▸ | CA7 | P43166 | 2/20 | 0.54 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.54 |
| ▸ | CA3 | P07451 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2178308 | 0.73 | HTR6 (0.48) | CA1CA2CA9CA12CA5A | |
| SCHEMBL2178473 | 0.73 | HTR6 (0.48) | CA1CA2CA9CA12CA5A | |
| SCHEMBL486788 | 0.73 | HTR6 (0.48) | CA1CA2CA9CA12CA5A | |
| Benzenesulfonamide SCHEMBL28194516 | 0.72 | CA2 (0.89) | CA1CA2CA9CA12CA5A | |
| SCHEMBL11679652 | 0.71 | HTR6 (0.46) | CA1CA2CA9CA12CA5A | |
| SCHEMBL28801429 | 0.71 | PSIP1 (0.45) | CA1CA2CA9CA12CA5A | |
| Benzenesulfonamide SCHEMBL6868390 | 0.71 | CA2 (1.00) | CA1CA2CA9CA12CA5A | |
| Benzenesulfonamide SCHEMBL1332409 | 0.71 | CA2 (1.00) | CA1CA2CA9CA12CA5A | |
| Benzenesulfonamide SCHEMBL729 | 0.71 | CA2 (1.00) | CA1CA2CA9CA12CA5A | |
| Benzenesulfonamide SCHEMBL29825137 | 0.71 | CA2 (1.00) | CA1CA2CA9CA12CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0173498-B1 | HERBICIDAL SULPHONIMIDAMIDE COMPOUNDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-04-18 | — | — | EP | claimed |
| EP-4654964-A1 | SULFONE-1H-PYRROLE-2-CARBOXAMIDE INHIBITORS OF SARS-COV-2 NSP14 METHYLTRANSFERASE AND DERIVATIVES THEREOF | The Rockefeller University (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20240382474-A1 | ENPP1 MODULATORS AND USES THEREOF | VIR BIOTECHNOLOGY INC (US) | 2024-11-21 | — | — | US | disclosed |
| WO-2024158875-A1 | SULFONE-1H-PYRROLE-2-CARBOXAMIDE INHIBITORS OF SARS-COV-2 NSP14 METHYLTRANSFERASE AND DERIVATIVES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 2024-08-02 | — | — | WO | disclosed |
| EP-3880659-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| EP-3658539-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis Inflammasome Research, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2019023147-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382474-A1 | ENPP1 MODULATORS AND USES THEREOF | ENPP1, ENPP2, ENPP3 | CA1 4856/4885CA2 4296/4885CA9 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.